Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma

International Journal of Gynecological Cancer

Volumn 18, Issue 2, 2008, Pages 369-372

  Arora, N ^a   Tewari, D ^b   Cowan, C ^a   Saffari, B ^a   Monk, B J ^a   Burger, R A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Bevacizumab; Fallopian tube cancer

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CASE REPORT; FEMALE; GYNECOLOGIC CANCER; HUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED;

EID: 40549084381     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01026.x     Document Type: Article

References (9)

1. DiSaia PJ, Creasman WT. Clinical gynecologic oncology. St. Louis : Mosby, 2002 : 377 84.
2. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005 3 : 902 5.
3. Burger RA, Sill M, Monk BJ, Greer B, Sorosky J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study [abstract]. ASCO Annual Meeting Proceedings 2005. Abstract 5009.
4. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006 102 : 140 4.
5. Garcia AA, Oza AM, Hirte H et al. Interim report of a phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian and primary peritoneal carcinoma: a california cancer consortium trial [abstract]. ASCO Annual Meeting Proceedings 2005. Abstract 5000.
6. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006 5 : 769 77.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 23 : 2335 42.
8. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 11 : 2184 91.
9. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 5 : 427 34.